Mural Oncology plc(MURA) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress Company remains on track in late-stage, potentially registrational trials of nemvaleukin alfa, with data readouts expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Candidate nominations for IL-18 and IL-12 programs expected in Q4 2024, and IND submission for Mural's IL18 program planned for Q4 2025 Mural reiterates guidance on projected ca ...